Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Hematologic Malignancy Clinical Trial

Official title:

A Prospective Study of Tocilizumab for the Prevention of Graft Failure and Graft-versus-Host Disease in Haplo-Cord Transplantation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04395222
• Other study ID #: 19-08020738
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: October 7, 2020
• Est. completion date: May 2027

Study information

• Verified date: September 2023
• Source: Weill Medical College of Cornell University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety of reducing and ultimately eliminating anti-thymocyte globulin (ATG) from the haplo-cord transplant conditioning regimen and replacing it with tocilizumab, an IL-6 receptor monoclonal antibody, to improve immune reconstitution and reduce relapse while preserving low rates of graft failure and graft versus host disease (GVHD).

Description:

This study is a prospective phase II non-inferiority study investigating tocilizumab as a potential alternative to anti-thymocyte globulin (ATG) in haplo-cord transplantation. It is a single-center study based at Weill Cornell Medicine/NewYork Presbyterian Hospital.

The hypothesis is that tocilizumab is a safe and effective alternative to ATG in haplo-cord transplantation, facilitating transient engraftment of the haplo-identical stem cell graft without prolonged neutropenia or second nadir prior to durable cord engraftment while also preventing graft versus host disease (GVHD).

This study plans to enroll patients with hematologic malignancies in need of alternate donor transplant. All subjects will be conditioned with fludarabine, melphalan and total body irradiation (TBI), followed by a single dose of tocilizumab 8 mg/kg on Day -1. Patients will be enrolled into 4 successive cohorts, initially administering the current standard 3 doses of ATG 1.5 mg/kg (total 4.5 mg/kg). In the absence of safety signals, we will drop one dose of ATG in successive cohorts until the drug ultimately has been eliminated.

The primary endpoint of the study is successful haplo-derived neutrophil engraftment. Treatment will only be of interest if there is evidence that this rate is greater than 60%. If there are 4 or fewer successes, that dose group will be deemed unacceptable and the next higher ATG dose for which there were 5 or more success will be expanded.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: May 2027
• Est. primary completion date: September 28, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject must have a confirmed diagnosis of one of the following:

1. Relapsed or refractory acute leukemia (myeloid or lymphoid)

2. Acute leukemia in first remission at high-risk for recurrence

3. Chronic myelogenous leukemia in chronic, accelerated phase or blast-crisis

4. Myelodysplastic syndromes

5. Chronic myeloproliferative disease

6. Recurrent, refractory or high-risk malignant lymphoma

7. Chronic lymphocytic leukemia, relapsed or with poor prognostic features

8. Multiple myeloma

9. Other hematological disorder in need of allogeneic transplant (e.g. blastoid dendritic cell neoplasm)

2. Age = 18 years.

3. Likely to benefit from allogeneic transplant in the opinion of the transplant physician.

4. An HLA-identical related or unrelated donor cannot be identified within an appropriate time frame.

5. Karnofsky Performance Status (KPS) of = 70%.

6. Acceptable organ function as defined below:

1. Serum bilirubin: <2.0 mg/dL

2. ALT (SGPT) <3x upper limit of normal (ULN)

3. Creatinine Clearance: >50 mL/min/1.73m2 (eGFR as estimated by the modified MDRD equation)

4. Left ventricular ejection fraction >40%

5. Pulmonary diffusion capacity >40% predicted

7. Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

1. Life expectancy is severely limited by concomitant illness or uncontrolled infection.

2. Evidence of chronic active hepatitis or cirrhosis

3. Uncontrolled HIV disease.

4. Pregnancy or lactation.

5. History of complicated diverticulitis, including fistulae, abscess formation or gastrointestinal perforation

6. History of allergic reactions attributed to compounds of similar chemical or biological composition as tocilizumab, including known allergies to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.

Related Conditions & MeSH terms

• Bone Marrow Transplant
• Hematologic Malignancy
• Hematologic Neoplasms
• Neoplasms

Intervention

Drug:
• Tocilizumab
Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen
• Fludarabine
Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen.
• Melphalan
Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen.
• Anti-thymocyte globulin (rabbit)
Anti-thymocyte globulin (ATG) 1.5 mg/kg

Radiation:
• Total Body Irradiation
Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen

Locations

Country	Name	City	State
United States	Weill Cornell Medical College	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Weill Medical College of Cornell University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects With Successful Haplo-derived Neutrophil Engraftment	This is defined as: Achieve an absolute neutrophil count (ANC) of 500 cells/microL for three consecutive days with the first on or prior to Day +21 post-transplant, AND; Absence of a second nadir - a drop in the ANC to <300 cells/microL for five consecutive days - after initial neutrophil recovery.	21 days post-transplant
Secondary	Progression-Free Survival	Time elapsed between Day 0 and progression of the underlying malignancy for which the transplant was performed, assessed up to 5 years post-transplant.	5 years post-transplant
Secondary	Overall Survival	Time elapsed between Day 0 and death from any cause, assessed up to 5 years post-transplant.	5 years post-transplant
Secondary	Transplant-Related Mortality	Proportion of deaths which cannot be explained by persistence, relapse or progression of the underlying malignancy once the preparative regimen starts, assessed up to 5 years post-transplant.	5 years post-transplant
Secondary	Proportion of Platelet Engraftment Success	Proportion of patients who successfully achieve platelet engraftment, defined as a platelet count of >20k/microL for three consecutive days without transfusion support for seven consecutive days.	6 months post-transplant
Secondary	Proportion of Failure of the Haplo-Graft	Proportion of patients with a failed haplo-graft, defined as the absence of neutrophil engraftment by Day +21 or a drop in the absolute neutrophil count to <0.3 cells/microL for five consecutive days occurring after initial neutrophil engraftment within the first 3 weeks post-transplantation (second nadir)	21 days post-transplant
Secondary	Proportion of Acute Graft-versus-Host Disease	Proportion of patients who develop acute graft-versus-host disease	1 year post-transplant
Secondary	Proportion of Chronic Graft-versus-Host Disease	Proportion of patients who develop chronic graft-versus-host disease	5 years post-transplant